ContraFect Corp (CFRX) Expected to Post Earnings of -$0.11 Per Share

Brokerages predict that ContraFect Corp (NASDAQ:CFRX) will post ($0.11) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for ContraFect’s earnings, with the highest EPS estimate coming in at ($0.09) and the lowest estimate coming in at ($0.11). ContraFect posted earnings of ($0.09) per share during the same quarter last year, which would indicate a negative year over year growth rate of 22.2%. The firm is scheduled to issue its next quarterly earnings results on Thursday, May 9th.

On average, analysts expect that ContraFect will report full-year earnings of ($0.38) per share for the current financial year, with EPS estimates ranging from ($0.44) to ($0.31). For the next year, analysts forecast that the company will post earnings of ($0.45) per share, with EPS estimates ranging from ($0.52) to ($0.36). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for ContraFect.

ContraFect (NASDAQ:CFRX) last posted its quarterly earnings results on Thursday, March 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.17.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in ContraFect by 8.3% during the 4th quarter. Geode Capital Management LLC now owns 377,908 shares of the biotechnology company’s stock valued at $578,000 after purchasing an additional 29,009 shares during the period. White Pine Capital LLC raised its stake in ContraFect by 24.9% during the 4th quarter. White Pine Capital LLC now owns 294,730 shares of the biotechnology company’s stock valued at $451,000 after purchasing an additional 58,725 shares during the period. Northern Trust Corp raised its stake in ContraFect by 46.5% during the 4th quarter. Northern Trust Corp now owns 114,131 shares of the biotechnology company’s stock valued at $175,000 after purchasing an additional 36,239 shares during the period. Trellus Management Company LLC raised its stake in ContraFect by 43.7% during the 4th quarter. Trellus Management Company LLC now owns 120,676 shares of the biotechnology company’s stock valued at $185,000 after purchasing an additional 36,721 shares during the period. Finally, Vanguard Group Inc raised its stake in ContraFect by 24.2% during the 3rd quarter. Vanguard Group Inc now owns 2,634,428 shares of the biotechnology company’s stock valued at $5,454,000 after purchasing an additional 512,940 shares during the period. 55.57% of the stock is currently owned by institutional investors.

Shares of NASDAQ CFRX traded down $0.01 during trading on Friday, hitting $0.59. The company had a trading volume of 1,818,549 shares, compared to its average volume of 2,154,591. The stock has a market capitalization of $47.22 million, a P/E ratio of -1.59 and a beta of -0.52. ContraFect has a 52 week low of $0.35 and a 52 week high of $2.93.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Read More: What is a Call Option?

Get a free copy of the Zacks research report on ContraFect (CFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.